Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website https://gr.elmerpub.com

Original Article

Volume 19, Number 4, August 2026, pages 184-189

Mirtazapine in Treating Functional Dyspepsia: A Systematic Review and Meta-Analysis

Figures

↓ Figure 1. PRISMA diagram outlining the process of selecting studies for meta-analysis.

↓ Figure 2. Forest plot of pooled effect sizes comparing mirtazapine and control treatment for functional dyspepsia symptom severity.

↓ Figure 3. Leave-one-out sensitivity analysis of mirtazapine versus control for functional dyspepsia symptom severity.

↓ Figure 4. Baujat plot displaying the effect of each study on heterogeneity.

Table

↓ **Table 1.** Patient Population, Intervention, and Other Key Characteristics of Included Studies in Our Meta-Analysis
Study	Population	Treatment group, n	Control group, n	Sex	Age	Duration	Dose	Other treatments	Symptom scale	Effect size (95% CI)
CI: confidence interval; FD: functional dyspepsia; NDSI: Nepean Dyspepsia Symptom Index.
Jiang 2016 [6]	Adults with weight loss and diagnosis of depression and FD	20	20	Treatment group: 8M/12F Control group: 7M/13F	Treatment group: 43.45 ± 11.50 Control group: 39.95 ± 6.84	8 weeks	30 mg	None	NDSI	−1.08 (−1.73 to −0.43)
Tack, 2016 [7]	Adults with weight loss and FD, without diagnosis of depression or anxiety	17	17	Treatment group: 3M/14F Control group: 2M/15F	Treatment group: 35.9 ± 2.3 Control group: 39.9 ± 3.5	8 weeks	15 mg	None	NDSI	−2.24 (−3.09 to −1.40)
Cao 2025 [8]	Adults with diagnosis of FD	58	59	Treatment group: 29M/29F Control group: 37M/22F	Treatment group: 43.93 ± 13.27 Control group: 43.58 ± 11.86	8 weeks	15 mg	Pancreatic enzyme supplement and domperidone	NDSI	−1.11 (−1.50 to −0.73)